|
1
|
Ferlay J, Colombet M, Soerjomataram I,
Mathers C, Parkin DM, Piñeros M, Znaor A and Bray F: Estimating the
global cancer incidence and mortality in 2018: GLOBOCAN sources and
methods. Int J Cancer. 144:1941–1953. 2019.
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hartman EK and Eslick GD: The prognosis of
women diagnosed with breast cancer before, during and after
pregnancy: A meta-analysis. Breast Cancer Res Treat. 160:347–360.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gupta GP and Massagué J: Cancer
metastasis: Building a framework. Cell. 127:679–695. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kang Y and Massagué J:
Epithelial-mesenchymal transitions: Twist in development and
metastasis. Cell. 118:277–279. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xu J, Lamouille S and Derynck R:
TGF-beta-induced epithelial to mesenchymal transition. Cell Res.
19:156–172. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan
A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nieman MT, Prudoff RS, Johnson KR and
Wheelock MJ: N-cadherin promotes motility in human breast cancer
cells regardless of their E-cadherin expression. J Cell Biol.
147:631–644. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Martin TA, Goyal A, Watkins G and Jiang
WG: Expression of the transcription factors snail, slug, and twist
and their clinical significance in human breast cancer. Ann Surg
Oncol. 12:488–496. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Islam SS, Mokhtari RB, El Hout Y, Azadi
MA, Alauddin M, Yeger H and Farhat WA: TGF-β1 induces EMT
reprogramming of porcine bladder urothelial cells into collagen
producing fibroblasts-like cells in a Smad2/Smad3-dependent manner.
J Cell Commun Signal. 8:39–58. 2014. View Article : Google Scholar
|
|
11
|
Divya T, Velavan B and Sudhandiran G:
Regulation of Transforming Growth Foctor-β/Smad mediated
epithelial-mesenchymal transition by celastrol provides protection
against bleomycin-induced pulmonary fibrosis. Basic Clin Pharmacol
Toxicol. 123:122–129. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shi Y and Massagué J: Mechanisms of
TGF-beta signaling from cell membrane to the nucleus. Cell.
113:685–700. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huang G, Du MY, Zhu H, Zhang N, Lu ZW,
Qian LX, Zhang W, Tian X, He X and Yin L: MiRNA-34a reversed
TGF-β-induced epithelial-mesenchymal transition via suppression of
SMAD4 in NPC cells. Biomed Pharmacother. 106:217–224. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hu H, Xu Z, Li C, Xu C, Lei Z, Zhang HT
and Zhao J: MiR-145 and miR-203 represses TGF-β-induced
epithelial-mesenchymal transition and invasion by inhibiting SMAD3
in non-small cell lung cancer cells. Lung Cancer. 97:87–94. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang L, Tong X, Zhou Z, Wang S, Lei Z,
Zhang T, Liu Z, Zeng Y, Li C, Zhao J, et al: Circular RNA
hsa_circ_0008305 (circPTK2) inhibits TGF-β-induced
epithelial-mesenchymal transition and metastasis by controlling
TIF1γ in non-small cell lung cancer. Mol Cancer. 17:1402018.
View Article : Google Scholar
|
|
16
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zamore PD and Haley B: Ribo-gnome: The big
world of small RNAs. Science. 309:1519–1524. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nazarov PV, Reinsbach SE, Muller A, Nicot
N, Philippidou D, Vallar L and Kreis S: Interplay of microRNAs,
transcription factors and target genes: Linking dynamic expression
changes to function. Nucleic Acids Res. 41:2817–2831. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li X, Wan X, Chen H, Yang S, Liu Y, Mo W,
Meng D, Du W, Huang Y, Wu H, et al: Identification of miR-133b and
RB1CC1 as independent predictors for biochemical recurrence and
potential therapeutic targets for prostate cancer. Clin Cancer Res.
20:2312–2325. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kano M, Seki N, Kikkawa N, Fujimura L,
Hoshino I, Akutsu Y, Chiyomaru T, Enokida H, Nakagawa M and
Matsubara H: miR-145, miR-133a and miR-133b: Tumor-suppressive
miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J
Cancer. 127:2804–2814. 2010. View Article : Google Scholar
|
|
21
|
Guo L, Bai H, Zou D, Hong T, Liu J, Huang
J, He P, Zhou Q and He J: The role of microRNA-133b and its target
gene FSCN1 in gastric cancer. J Exp Clin Cancer Res. 33:992014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nohata N, Hanazawa T, Enokida H and Seki
N: microRNA-1/133a and microRNA-206/133b clusters: Dysregulation
and functional roles in human cancers. Oncotarget. 3:9–21. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang QY, Zhou CX, Zhan MN, Tang J, Wang
CL, Ma CN, He M, Chen GQ, He JR and Zhao Q: MiR-133b targets Sox9
to control pathogenesis and metastasis of breast cancer. Cell Death
Dis. 9:7522018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Thor A: A revised staging system for
breast cancer. Breast J. 10(Suppl 1): S15–S18. 2015. View Article : Google Scholar
|
|
25
|
Varkonyi-Gasic E, Wu R, Wood M, Walton EF
and Hellens RP: Protocol: A highly sensitive RT-PCR method for
detection and quantification of microRNAs. Plant Methods. 3:122007.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
27
|
Wolter JM, Kotagama K, Pierre-Bez AC,
Firago M and Mangone M: 3′LIFE: A functional assay to detect miRNA
targets in high-throughput. Nucleic Acids Res. 42:e1322014.
View Article : Google Scholar
|
|
28
|
Liu RY, Zeng Y, Lei Z, Wang L, Yang H, Liu
Z, Zhao J and Zhang HT: JAK/STAT3 signaling is required for
TGF-β-induced epithelial-mesenchymal transition in lung cancer
cells. Int J Oncol. 44:1643–1651. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fang Y, Chen Y, Yu L, Zheng C, Qi Y, Li Z,
Yang Z, Zhang Y, Shi T, Luo J and Liu M: Inhibition of breast
cancer metastases by a novel inhibitor of TGFβ receptor 1. J Natl
Cancer Inst. 105:47–58. 2013. View Article : Google Scholar
|
|
30
|
Cortez VS, Ulland TK, Cervantes-Barragan
L, Bando JK, Robinette ML, Wang Q, White AJ, Gilfillan S, Cella M
and Colonna M: SMAD4 impedes the conversion of NK cells into
ILC1-like cells by curtailing non-canonical TGF-β signaling. Nat
Immunol. 18:995–1003. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nagy Á, Lánczky A, Menyhárt O and Győrffy
B: Validation of miRNA prognostic power in hepatocellular carcinoma
using expression data of independent datasets. Sci Rep. 8:92272018.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dawood S, Broglio K, Buzdar AU, Hortobagyi
GN and Giordano SH: Prognosis of women with metastatic breast
cancer by HER2 status and trastuzumab treatment: An
institutional-based review. J Clin Oncol. 28:92–98. 2010.
View Article : Google Scholar :
|
|
33
|
Nicoloso MS, Spizzo R, Shimizu M, Rossi S
and Calin GA: MicroRNAs-the micro steering wheel of tumour
metastases. Nat Rev Cancer. 9:293–302. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chan M, Liaw CS, Ji SM, Tan HH, Wong CY,
Thike AA, Tan PH, Ho GH and Lee AS: Identification of circulating
microRNA signatures for breast cancer detection. Clin Cancer Res.
19:4477–4487. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wen D, Li S, Ji F, Cao H, Jiang W, Zhu J
and Fang X: miR-133b acts as a tumor suppressor and negatively
regulates FGFR1 in gastric cancer. Tumour Biol. 34:793–803. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Crawford M, Batte K, Yu L, Wu X, Nuovo GJ,
Marsh CB, Otterson GA and Nana-Sinkam SP: MicroRNA 133B targets
pro-survival molecules MCL-1 and BCL2L2 in lung cancer. Biochem
Biophys Res Commun. 388:483–489. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hu G, Chen D, Li X, Yang K, Wang H and Wu
W: miR-133b regulates the MET proto-oncogene and inhibits the
growth of colorectal cancer cells in vitro and in vivo. Cancer Biol
Ther. 10:190–197. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Qin W, Dong P, Ma C, Mitchelson K, Deng T,
Zhang L, Sun Y, Feng X, Ding Y, Lu X, et al: MicroRNA-133b is a key
promoter of cervical carcinoma development through the activation
of the ERK and AKT1 pathways. Oncogene. 31:4067–4075. 2012.
View Article : Google Scholar
|
|
39
|
Ventura A and Jacks T: MicroRNAs and
cancer: Short RNAs go a long way. Cell. 136:586–591. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lei Z, Xu G, Wang L, Yang H, Liu X, Zhao J
and Zhang HT: MiR-142-3p represses TGF-β-induced growth inhibition
through repression of TGFβR1 in non-small cell lung cancer. FASEB
J. 28:2696–2704. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Akhurst RJ and Derynck R: TGF-beta
signaling in cancer-a double-edged sword. Trends Cell Biol.
11:S44–S51. 2001.PubMed/NCBI
|
|
42
|
Fukai Y, Fukuchi M, Masuda N, Osawa H,
Kato H, Nakajima T and Kuwano H: Reduced expression of transforming
growth factor-beta receptors is an unfavorable prognostic factor in
human esophageal squamous cell carcinoma. Int J Cancer.
104:161–166. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Li Y, Liu G, Li X, Dong H, Xiao W and Lu
S: Long non-coding RNA SBF2-AS1 promotes hepatocellular carcinoma
progression through regulation of miR-140-5p-TGFβR1 pathway.
Biochem Biophys Res Commun. 503:2826–2832. 2018. View Article : Google Scholar : PubMed/NCBI
|
